Grabar Law Office

Directions Website Contact the practice

Grabar Law Office Specializing in Antitrust, Securities, and Consumer Class Action Litigation. Offering Clients Expert Legal Advice and Value Added Solutions.

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation ...
10/14/2026

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your Behalf

Aardvark Therapeutics, Inc. (NASDAQ: AARD):
Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.

What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects of the Company’s lead drug candidate, ARD-101.

If you purchased Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares on or shortly after the Company’s February 13, 2025 IPO, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. You are encouraged to visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085 to learn more.

What is Alleged? According to the recently filed securities complaint, Aardvark Therapeutics, Inc. (NASDAQ: AARD) IPO offering documents represented that ARD-101 had been “well-tolerated” in earlier clinical trials, had limited systemic absorption, and had demonstrated no serious adverse events. The complaint alleges that the offering documents were materially false or misleading because they failed to disclose that ARD-101 was less safe than investors had been led to believe and that its clinical, regulatory, and commercial prospects were therefore overstated.

The complaint further alleges that similar representations concerning ARD-101’s safety continued after the IPO. For example, Company representatives subsequently described ARD-101 as having a “very, very clean” safety profile and represented that its limited systemic exposure reduced the likelihood of side effects.

Then, on February 27, 2026, Aardvark announced that it was voluntarily pausing enrollment and dosing in the Phase 3 HERO trial after identifying reversible cardiac observations during safety monitoring in a healthy-volunteer study. Following the announcement, Aardvark’s stock price allegedly declined approximately 56%, closing at $5.47 per share on March 2, 2026.
Then, on May 14, 2026, Aardvark announced that the FDA had placed a full clinical hold on the investigational new drug application for ARD-101, including the Phase 3 HERO trial and its open-label extension. According to the complaint, Aardvark’s stock declined another 32.1% the following day, closing at $4.57 per share.

What Can You Do Now? If you purchased Aardvark shares at or shortly after the February 13, 2025 IPO, and continue to own those shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085 to learn more. $AARD

Coastal Financial Corporation (NASDAQ: CCB):
Grabar Law Office is investigating claims on behalf of shareholders of Coastal Financial Corporation (NASDAQ: CCB).
What is This Investigation About? This investigation concerns possible breaches of fiduciary duties and other alleged misconduct by certain officers and directors of the Company.

Current Coastal Financial Corporation (NASDAQ: CCB) shareholders who have held Coastal shares since prior to October 28, 2024, are encouraged visit https://grabarlaw.com/the-latest/coastal-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever.

What is Alleged? A recently filed federal securities fraud class action alleges that Coastal Financial Corporation (NASDAQ: CCB), through certain of its current and former executives, made materially false and misleading statements concerning the growth and credit quality of Coastal’s CCBX business, the adequacy of the Company’s risk-management and credit-monitoring practices, and the credit protections provided by CCBX partner indemnification agreements. Specifically, that complaint alleges that, while Coastal represented that CCBX growth was being pursued in a disciplined manner with an emphasis on credit quality and risk management, defendants failed to disclose that: 1) the credit quality of a substantial CCBX partner loan portfolio consisting of approximately $500 million in loans, or nearly 23% of all CCBX loans, had materially deteriorated; 2) the deterioration exposed Coastal to significant credit losses despite representations concerning the protections provided by CCBX partner indemnification agreements; and 3) Coastal’s risk-management and credit-monitoring practices were allegedly inadequate to identify, properly account for and mitigate the deterioration and resulting risks.

The truth was revealed when, on July 30, 2026, Coastal announced its second-quarter 2026 financial results and reported a surprise GAAP net loss of $42.1 million, driven primarily by a $68.8 million credit expense associated with a single CCBX partner relationship. Coastal also disclosed that the affected portfolio consisted of approximately $500 million in underlying loans, together with the related reimbursement exposure. The complaint additionally alleges that Chief Executive Officer Eric M. Sprink sold approximately $12 million of Coastal common stock during the Class Period, while former CFO Joel Edwards sold approximately $3.8 million. It is alleged that those sales occurred before the deterioration of the CCBX partner portfolio and Coastal’s resulting exposure were disclosed to investors.

What Can You Do Now? If you have owned Coastal Financial Corporation (NASDAQ: CCB) shares since prior to October 28, 2024, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/coastal-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085 to learn more. $CCB

New Era Energy & Digital, Inc. (NASDAQ: NUAI):
Grabar Law Office is investigating claims on behalf of shareholders of New Era Energy & Digital, Inc. (NASDAQ: NUAI) (formerly known as New Era Helium (NASDAQ: NEHC)).

What Is This Investigation About? The investigation concerns whether New Era and certain of its officers and directors breached their fiduciary duties owed to the Company.

If you purchased New Era Energy & Digital, Inc. (NASDAQ: NUAI) shares (formerly known as New Era Helium (NASDAQ: NEHC)), on or shortly after the Company’s December 9, 2024 IPO, and continue to hold shares today, please visit https://grabarlaw.com/the-latest/newera-shareholder-investigation-2/ contact Joshua H. Grabar at [email protected], or call 267-507-6085. You may be able to seek corporate governance reforms, the return of funds back to the Company, and a court-approved incentive award at no cost to you whatsoever.

What is Alleged? According to a recently filed federal securities fraud class action complaint, New Era Energy & Digital, Inc. (NASDAQ: NUAI), through certain of its officers, allegedly made false and misleading statements concerning the Company’s Texas Critical Data Centers project, permitting progress, environmental liabilities, and related-party oil and gas transactions. The complaint alleges that New Era overstated its progress in obtaining regulatory permits and advancing its purported flagship Texas Critical Data Centers project, while publicly touting “tangible progress across all fronts including engineering, permitting, regulatory filings, and land expansion.” According to the complaint, the Company also represented to investors that it was making substantial progress toward a large-scale AI and high-performance computing data center campus in West Texas. It is alleged that that New Era’s AI pivot was largely a “fantasy,” and that despite Company representations regarding permitting progress, “no applications have even been submitted” for required construction and environmental permits. It is further alleged that a substantial number of New Era’s gas wells had been acquired from bankrupt entities tied to Company insiders and accused management of engaging in financial practices designed to enrich insiders while avoiding environmental cleanup obligations.

On December 29, 2025, reports emerged that the New Mexico Attorney General had filed suit against New Era, its subsidiary Solis Partners, LLC, and Company CEO Everett Willard Gray II, alleging a “fraudulent oil-and-gas scheme” involving self-dealing transactions, shell entities, and strategic bankruptcies designed to evade plugging and remediation obligations for inactive wells. According to that complaint, the alleged scheme involved transferring wells among affiliated entities while leaving environmental liabilities behind in bankruptcy proceedings.

What Can You Do Now? If you purchased or otherwise acquired New Era Energy & Digital, Inc. (NASDAQ: NUAI) shares (formerly known as New Era Helium (NASDAQ: NEHC)), on or shortly after its December 9, 2024 IPO, and continue to hold shares today, you can seek corporate governance reforms, the return of funds back to the Company, and a court-approved incentive award at no cost to you whatsoever. Visit https://grabarlaw.com/the-latest/newera-shareholder-investigation-2/, email Joshua Grabar at [email protected], or call us at 267-507-6085. $NUAI $NEHC

The Simply Good Foods Company (NASDAQ: SMPL):
Grabar Law Office is investigating claims on behalf of shareholders of The Simply Good Foods Company (NASDAQ: SMPL).

What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased The Simply Good Foods Company (NASDAQ: SMPL) shares before February 24, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit https://grabarlaw.com/the-latest/smpl-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085 to learn more.

What is Alleged? As alleged in a recently filed securities fraud class action Complaint, The Simply Good Foods Company (NASDAQ: SMPL), through certain of its officers, made materially false and misleading statements and/or failed to disclose materially adverse facts pertaining to the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) that Simply Good Foods had lost key managerial personnel following the acquisition of OWYN necessary for the successful integration of the acquired OWYN assets; (2) that Simply Good Foods had materially increased its general and administrative spending to compensate for the loss of key managerial personnel; (3) the addition of a new pea protein supplier for OWYN prior to the acquisition had created significant product quality issues which had negatively impacted the product; (4) Simply Good Foods had engaged in promotional activities for OWYN products above its historical practices, eroding margins; (5) that, in order to stem the margin erosion, Simply Good Foods had cut brand support and marketing, further depressing product sales; (6) as a result of the above, the OWYN acquisition had largely failed to achieve its key strategic goals, the integration of OWYN had run into severe operational and ex*****on problems, and the business and operational results for the OWYN segment had been materially negatively impacted, undermining the acquisitions economic rationale; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

What Can You Do Now? If you purchased The Simply Good Foods Company (NASDAQ: SMPL) shares before February 24, 2024, and still hold shares today, please visit https://grabarlaw.com/the-latest/smpl-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $SMPL

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: [email protected]

Discover LongTerm Shareholder Claims with Grabar Law Office and explore Grabar Law Office built for your goals today.

Important Notice to Long-Term Shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL); Ardelyx, Inc. (NYSE: ARDX); Aar...
10/05/2026

Important Notice to Long-Term Shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL); Ardelyx, Inc. (NYSE: ARDX); Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI): Grabar Law Office is Investigating Claims on Your Behalf

Anavex Life Sciences Corp. (NASDAQ: AVXL):
Grabar Law Office is investigating claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL).
What is The Investigation About? Grabar Law Office is investigating whether certain officers and directors of Anavex breached their fiduciary duties owed to the Company and its shareholders.

Current Anavex Life Sciences Corp. (NASDAQ: AVXL) shareholders who have held Anavex shares since on or before November 26, 2025, are encouraged to visit https://grabarlaw.com/the-latest/anavex-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever.

What is Alleged? As alleged in a recently filed federal securities fraud class action complaint, Anavex Life Sciences Corp. (NASDAQ: AVXL), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) Anavex lacked adequate internal controls; (ii) Anavex understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling; and (iii) as a result, defendants’ statements about Anavex’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On May 6, 2026, Anavex filed a current report on Form 8-K with the United States Securities and Exchange Commission (“SEC”), allegedly stating that “[o]n April 30, 2026, a special committee (the “Special Committee”) composed of independent directors of the Board of Directors (the “Board”) of Anavex Life Sciences Corp. (the “Company”) terminated the employment of Christopher Missling, PhD as the Company’s Chief Executive Officer for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr. Missling and the Company, as amended and restated), effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy.” On this news, the price of Anavex stock declined nearly 1%, according to the complaint.

Then, on May 11, 2026, after market hours, Anavex filed with the SEC a notification of late filing on Form 12b-25, allegedly stating that Anavex was “unable to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026,” due in part to Anavex’s internal review of “certain matters related to the termination of Dr. Missling.” On this news, the price of Anavex stock fell nearly 6%, according to the complaint.
Finally, on August 28, 2026, after market hours, Anavex filed with the SEC an amended annual report on Form 10-K/A for the fiscal year ended September 30, 2025, allegedly disclosing in part that “[a]s a result of the review by the Special Committee, management, in consultation with the Audit Committee of the Board (the “Audit Committee”), concluded that there was a material weakness in internal control over financial reporting that existed at September 30, 2025,” and that Anavex’s “disclosure controls and procedures were not effective as of September 30, 2025, due to the material weakness in internal control over financial reporting as described above.” That same day, Anavex allegedly filed with the SEC its quarterly reports for the periods ending March 31, 2026 and June 30, 2026, which both contained the following disclosure: “[f]ollowing the previously disclosed termination of our former CEO in April 2026, management has determined that our disclosure controls and procedures and our internal controls over financial reporting were not effective as of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026.” On this news, the price of Anavex stock declined more than 6%, according to the complaint.

What Can You Do Now? If you are a current Anavex Life Sciences Corp. (NASDAQ: AVXL) shareholder who has held Anavex shares since on or before November 26, 2025, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. If you would like to learn more about this matter, please visit https://grabarlaw.com/the-latest/anavex-shareholder-investigation/, contact us at [email protected], or call Joshua H. Grabar at 267-507-6085. Alternatively, if you purchased Anavex shares between November 26, 2025 and August 28, 2026, you can participate in the class action. $AVXL

Ardelyx, Inc. (NYSE: ARDX):
Grabar Law Office is investigating whether certain officers and directors of Ardelyx, Inc. (NYSE: ARDX).

What is The Investigation About? The investigation concerns whether certain officers and directors breached their fiduciary duties owed to the Company and its shareholders.
If you have held Ardelyx, Inc. (NYSE: ARDX) shares since on or before January 13, 2025, visit https://grabarlaw.com/the-latest/ardx-shareholder-investigation/, contact us at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. Alternatively, investors who purchased or otherwise acquired Ardelyx common stock between January 13, 2025, and August 6, 2026, inclusive can participate in the class action.

What is Alleged? As alleged in a recently filed federal securities fraud class action complaint, Ardelyx, Inc. (NYSE: ARDX), through certain of its officers, provided investors with material information concerning Ardelyx’s fiscal year 2026 revenue outlook for its two core drug products, XPHOZAH and IBSRELA, as well as their anticipated long-term growth. Defendants’ statements included, among other things, confidence in the Company's continued commercial growth and ability to execute its commercial strategy to overcome payer and patient-access barriers, and its ability to achieve its projected revenue guidance and long-term growth targets.

It is alleged that Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Ardelyx’s commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Ardelyx’s securities at artificially inflated prices.

It is further alleged that the truth emerged after the market closed on August 6, 2026, when Ardelyx issued a press release a reduction in its full-year 2026 IBSRELA revenue guidance and withdrawal of its long-term XPHOZAH revenue guidance. Management attributed the reduction on significantly increased payer utilization-management processes that restricted patient access to IBSRELA and slowed new-patient starts. Further, Defendants withdrew their long-term XPHOZAH revenue guidance due to “evolving market dynamics” and uncertainty regarding future growth projections.

What Can You Do Now? Current Ardelyx, Inc. (NYSE: ARDX) shareholders who have held Ardelyx shares since on or before January 13, 2025, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/ardx-shareholder-investigation/, contact us at [email protected], or call 267-507-6085. Alternatively, investors who purchased or otherwise acquired Ardelyx common stock between January 13, 2025, and August 6, 2026, inclusive can participate in the class action. $ARDX

Aardvark Therapeutics, Inc. (NASDAQ: AARD):
Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.

What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects of the Company’s lead drug candidate, ARD-101.

If you purchased Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares on or shortly after the Company’s February 13, 2025 IPO, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. You are encouraged to visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085 to learn more.

What is Alleged? According to the recently filed securities complaint, Aardvark Therapeutics, Inc. (NASDAQ: AARD) IPO offering documents represented that ARD-101 had been “well-tolerated” in earlier clinical trials, had limited systemic absorption, and had demonstrated no serious adverse events. The complaint alleges that the offering documents were materially false or misleading because they failed to disclose that ARD-101 was less safe than investors had been led to believe and that its clinical, regulatory, and commercial prospects were therefore overstated.

The complaint further alleges that similar representations concerning ARD-101’s safety continued after the IPO. For example, Company representatives subsequently described ARD-101 as having a “very, very clean” safety profile and represented that its limited systemic exposure reduced the likelihood of side effects.

Then, on February 27, 2026, Aardvark announced that it was voluntarily pausing enrollment and dosing in the Phase 3 HERO trial after identifying reversible cardiac observations during safety monitoring in a healthy-volunteer study. Following the announcement, Aardvark’s stock price allegedly declined approximately 56%, closing at $5.47 per share on March 2, 2026.
Then, on May 14, 2026, Aardvark announced that the FDA had placed a full clinical hold on the investigational new drug application for ARD-101, including the Phase 3 HERO trial and its open-label extension. According to the complaint, Aardvark’s stock declined another 32.1% the following day, closing at $4.57 per share.

What Can You Do Now? If you purchased Aardvark shares at or shortly after the February 13, 2025 IPO, and continue to own those shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085 to learn more. $AARD

GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI)
Grabar Law Office is investigating claims on behalf of shareholders of GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO).

What Is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO) shares prior to November 3, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. You are encouraged to visit https://grabarlaw.com/the-latest/gpgi-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085.

What Is Alleged? It is alleged in a recently filed federal securities fraud class action complain that GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) defendants had materially overstated the value of Husky; (ii) Husky was not on track to achieve the revenue and Adjusted EBITDA targets provided in the proxy statement and such targets lacked a reasonable basis in objective fact; (iii) a primary motivation of the Husky Acquisition was to generate millions of dollars in fees for Resolute Holdings and the individual defendants, rather than to create long-term value for CompoSecure shareholders; and (iv) as a result of the above, defendants had materially misrepresented the business, prospects, and expected financial results of GPGI and Husky as a combined business.

What Can You Do Now? If you purchased GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO) shares prior to November 3, 2025, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/gpgi-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. $GPGI $CMPO

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: [email protected]

Investigations GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF GPGI, INC. f/k/a COMPOSECURE, INC. (NYSE: GPGI; CMPO) Grabar Law Office

10/01/2026

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Ardelyx, Inc. (NYSE: ARDX)

What is The Investigation About? Grabar Law Office is investigating whether certain officers and directors of Ardelyx, Inc. (NYSE: ARDX) breached their fiduciary duties owed to the Company and its shareholders.

If you have held Ardelyx, Inc. (NYSE: ARDX) shares since on or before January 13, 2025, visit https://grabarlaw.com/the-latest/ardx-shareholder-investigation/, contact us at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. Alternatively, investors who purchased or otherwise acquired Ardelyx common stock between January 13, 2025, and August 6, 2026, inclusive can participate in the class action.

What is Alleged? As alleged in a recently filed federal securities fraud class action complaint, Ardelyx, Inc. (NYSE: ARDX), through certain of its officers, provided investors with material information concerning Ardelyx’s fiscal year 2026 revenue outlook for its two core drug products, XPHOZAH and IBSRELA, as well as their anticipated long-term growth. Defendants’ statements included, among other things, confidence in the Company's continued commercial growth and ability to execute its commercial strategy to overcome payer and patient-access barriers, and its ability to achieve its projected revenue guidance and long-term growth targets.

It is alleged that Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Ardelyx’s commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Ardelyx’s securities at artificially inflated prices.

It is further alleged that the truth emerged after the market closed on August 6, 2026, when Ardelyx issued a press release a reduction in its full-year 2026 IBSRELA revenue guidance and withdrawal of its long-term XPHOZAH revenue guidance. Management attributed the reduction on significantly increased payer utilization-management processes that restricted patient access to IBSRELA and slowed new-patient starts. Further, Defendants withdrew their long-term XPHOZAH revenue guidance due to “evolving market dynamics” and uncertainty regarding future growth projections.

What Can You Do Now? Current Ardelyx, Inc. (NYSE: ARDX) shareholders who have held Ardelyx shares since on or before January 13, 2025, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/ardx-shareholder-investigation/, contact us at [email protected], or call 267-507-6085. Alternatively, investors who purchased or otherwise acquired Ardelyx common stock between January 13, 2025, and August 6, 2026, inclusive can participate in the class action.

Attorney Advertising Disclaimer

$ARDX

Address

1650 Market Street, Suite 3600
Philadelphia, PA
19103

Alerts

Be the first to know and let us send you an email when Grabar Law Office posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Grabar Law Office:

Shortcuts

Share